Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

Jan. 19th, 2016: Aurgalys publishes new analyst report on Abivax [Euronext: ABVX]

janvier 19, 2016

Paris- Evry, France, Jan. 19th, 2016 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development, and equity research services, publishes a new report on Abivax.

« Abivax published positive Phase 2a results for its product candidate ABX464, indicated for HIV patients management. These results are the first clinical proof of concept observed in human patients. Our target price for Abivax as of January 18th, 2016, is €29.30/share. »

You can download the coverage initiation report at the following link:

Comments are closed.